Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × olaratumab × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 17 Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

3-Iodobenzylguanidine 9 Magnetic Resonance Spectroscopy 5 Cyclophosphamide 5 Amifampridine 5 trametinib 4 pembrolizumab 4 nilotinib 4 gallium 68 PSMA-11 4 fludarabine 4 elotuzumab 4 dabrafenib 4 Nivolumab 4 Afatinib 4 midostaurin 3 fludarabine phosphate 3 Prednisone 3 Ipilimumab 3 Everolimus 3 Bortezomib 3 Abiraterone Acetate 3 venetoclax 2 veliparib 2 tucatinib 2 tempol 2 talimogene laherparepvec 2 selinexor 2 ruxolitinib 2 regorafenib 2 ponatinib 2 pomalidomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and Company

Approved for marketing

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡